Summary
MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Breslow DS (1976) Biologically active synthetic polymers. Pure Appl Chem 46:103
Breslow DS, Edwards EI, Newburg NR (1973) Divinyl ethermaleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity. Nature (London) 246:160
Dean JH, Padarthsingh ML, Keys L (1978) Response of murine leukemia to combined BCNU-maleic anhydride-vinyl ether (MVE) adjuvant therapy and correlation with macrophage activation by MVE in the in vitro growth inhibition assay. Cancer Treat Rep 62:1807
Giron DJ, Schmidt JP, Ball RJ, Pindak FF (1972) Effect of interferon inducers and interferon on bacterial infections. Anti-microb Agents Chemother 1:80
Morahan PS, Barnes DW, Munson AE (1978) Relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinylether (MVE) polyanions. Cancer Treat Rep 62:1977
Munson AE, Regelson W, Wooles WR (1969) The protective effect of pyran copolymer on the pathophysiology of varied microorganisms and transplanted tumors in mice (Abstract 12). Sixth Annual Meeting of the J Reticuloendothelial Society, p 632
Nussenzweig RS, Vilcek J, Jahiel R (1969) Effects of a synthetic interferon inducer on the course of rodent malaria. Fed Proc 28:815
Pavlidis NA, Schultz RM, Chirigos MA, Luetzeler J (1978) Effect of maleic anhydride-divinylether copolymers on experimental metastases and macrophage tumoricidal function. Cancer Treat Rep 62:1817
Pearson, JW, Chirigos MA, Chaparas SD, Sher NA (1974) Combined drug and immunostimulation therapy against a syngeneic murine leukemia. J Natl Cancer Inst 52:463
Regelson W (1985) The biological activity of the synthetic polyanion, pyran copolymer (Diveema, MVE, 46015) and the heterocyclic bis DEAE fluorenone derivative, tilorone and congeners: Clinical and laboratory effects of these agents as modulators of host resistance. In: Mitchell MS (ed) International Encyclopedia of Pharmacology and Therapeutics. The modulation of immunity. Pergamon Press, New York, 115:429–472
Regelson W (1986) Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy. J Bioactive Compatible Polymers 1:84–107
Regelson W, Parker G (1986) The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest 4:29–42
Regelson W, Shnider BI, Colsky J, Olson KB, Holland JF, Johnston CL, Dennis LH (1978) Clinical study of the synthetic polyanion pyran copolymer and its role in future clinical trials. In: Chirigos MA (ed) Progress in Cancer Research and Therapy. Raven Press, New York 7:469
Rinehart JJ, Young DC, Neidhart JA (1983) Evaluation of the immunologic and toxicological properties of MVE-II in Phase I trials. Cancer Res 43:2358
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rinehart, J., LaForge, J., Gochnour, D. et al. Phase II trial of MVE-II in metastic malignant melanoma. Cancer Immunol Immunother 24, 244–246 (1987). https://doi.org/10.1007/BF00205637
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00205637